Clinical Prognostic Factors and Treatment Outcome of Aggressive Non-Hodgkin's Lymphoma in Elderly Patients

Jung Hye Choi(Hanyang University Guri Hospital), In Soon Kim(Hanyang University), Moran Ki(National Cancer Center), Il Young Choi(Hanyang University), Myung‐Ju Ahn(Sungkyunkwan University), Ho Suk Oh(Hanyang University), Young Yuel Lee(Hanyang University)

Cancer Research and Treatment

August 31, 2001

10.4143/crt.2001.33.4.324

Cited by 4

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

|New England Journal of Medicine|2016|3.3k

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

|The Lancet|2018|1.7k

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

|The Lancet Oncology|2019|537